In this section:

14 June 2018

UPDATE: New Biologic Treatment Draft-Approved for Psoriasis

The National Institute for Health and Care Excellence (NICE) has today published its Final Appraisal Determination on the use of guselkumab (Tremfya) for severe psoriasis in England and Wales.

Guselkumab (Tremfya) is recommended to treat severe psoriasis, where people have not had adequate results from conventional systemic treatments, or cannot take them.

Tremfya blocks the activity of interleukin 23 (IL-23), a chemical ’messenger’ in the immune system that signals other cells to cause inflammation. In people with psoriasis the immune system is overactive and creates too much inflammation, which leads to the development of psoriasis symptoms. By blocking IL-23, Tremfya aims to prevent some of that inflammation from occurring, leading to an improvement in psoriasis for some people who take it. There is currently one other biologic medication available that blocks the activity of IL-23 available for people with severe psoriasis, called Stelara (ustekinumab).

UPDATE - 14th June 2018

NICE has now published final guidance on the use of guselkumab (Tremfya) in severe psoriasis. Please click here to read the final guidance, or click here for more information on Tremfya.

The Psoriasis Association is the UK's leading national charity and membership organisation for people affected by psoriasis – patients, families, carers and health professionals Read More >

Get in touch

The Psoriasis Association Dick Coles House 2 Queensbridge Northampton NN4 7BF

Email: mail@psoriasis-association.org.uk

Tel :
01604 251 620
Fax :
01604 251 621
Registered with Fundraising Regulator -

© The Psoriasis Association Registered Charity: 257414 Scotland: SC039886 Privacy PolicyCookies

Site by Spoken Image | glitterfish

We use cookies to help us provide you with a better service, but do not track anything that can be used to personally identify you.

If you prefer us not to set these cookies, please visit our Cookie Settings page or continue browsing our site to accept them.